Related Experiment Video

Updated: Aug 13, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Respiratory syncytial virus prophylaxis--the story so far

E A F Simoes1, J R Groothuis

  • 1Department of Paediatrics, The University of Colorado School of Medicine and The Children's Hospital, Denver 80218, USA.

Respiratory Medicine
|May 9, 2002
PubMed

Insights

Palivizumab, a monoclonal antibody, offers effective prophylaxis against respiratory syncytial virus (RSV) hospitalizations in high-risk children. This passive immunoprophylaxis option has demonstrated safety and efficacy in clinical trials worldwide.

Area of Science:

  • Pediatrics
  • Virology
  • Immunology

Background:

  • Respiratory syncytial virus (RSV) is a highly contagious pathogen causing significant morbidity and mortality in high-risk children.
  • Current RSV therapies are sub-optimal, focusing on symptom management rather than direct treatment.
  • Developing an effective RSV vaccine has faced considerable challenges since the virus's discovery.

Purpose of the Study:

  • To evaluate the efficacy and safety of palivizumab as a passive immunoprophylaxis for respiratory syncytial virus (RSV).
  • To assess the impact of palivizumab on RSV-related hospitalizations in high-risk pediatric populations.

Main Methods:

  • Review of clinical trial and outcomes data for palivizumab.
  • Analysis of safety and efficacy observations from post-approval studies.

Main Results:

  • Palivizumab significantly reduced RSV-related hospitalizations in North America and Europe.
  • The monoclonal antibody demonstrated a favorable safety profile with few adverse effects.
  • Ongoing data collection continues to support initial findings on palivizumab's safety and efficacy.

Conclusions:

  • Passive immunoprophylaxis with palivizumab is a viable and effective alternative to active immunization for RSV prevention.
  • Palivizumab provides a crucial tool for reducing the burden of RSV in high-risk children.
  • Continued monitoring and data analysis reinforce the established safety and efficacy of palivizumab.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...